Mitsiades CS - Search Results

1

The use of novel agents in the treatment of relapsed and refractory multiple myeloma.

Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG. Laubach JP, et al. Among authors: mitsiades cs. Leukemia. 2009 Dec;23(12):2222-32. doi: 10.1038/leu.2009.179. Epub 2009 Sep 10. Leukemia. 2009. PMID: 19741729 Free PMC article. Review.

2

Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.

Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Mitsiades N, et al. Among authors: mitsiades cs. Expert Opin Investig Drugs. 2001 Aug;10(8):1521-30. doi: 10.1517/13543784.10.8.1521. Expert Opin Investig Drugs. 2001. PMID: 11772267

3

The research mission in myeloma.

Richardson PG, San-Miguel J, Lonial S, Reece D, Jakubowiak A, Hussein M, Jagannath S, Mitsiades CS, Raje N, Kaufman J, Avigan D, Ghobrial I, Schlossman RL, Munshi N, Dalton W, Anderson KC. Richardson PG, et al. Among authors: mitsiades cs. Leukemia. 2009 Feb;23(2):422-3; author reply 423-4. doi: 10.1038/leu.2008.209. Epub 2008 Aug 7. Leukemia. 2009. PMID: 18685616 No abstract available.

4

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC. Mitsiades CS, et al. Among authors: mitsiades n. Blood. 2001 Aug 1;98(3):795-804. doi: 10.1182/blood.v98.3.795. Blood. 2001. PMID: 11468181 Free article.

5

A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice.

Hu Y, Zheng M, Gali R, Tian Z, Topal Görgün G, Munshi NC, Mitsiades CS, Anderson KC. Hu Y, et al. Among authors: mitsiades cs. Blood Cancer J. 2013 Nov 1;3(11):e156. doi: 10.1038/bcj.2013.53. Blood Cancer J. 2013. PMID: 24185503 Free PMC article.

6

Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.

Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC. Mitsiades N, et al. Among authors: mitsiades cs. Expert Opin Investig Drugs. 2001 Jun;10(6):1075-84. doi: 10.1517/13543784.10.6.1075. Expert Opin Investig Drugs. 2001. PMID: 11772236 Review.

7

Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases.

Mitsiades N, Poulaki V, Mitsiades CS, Koutras DA, Chrousos GP. Mitsiades N, et al. Among authors: mitsiades cs. Trends Endocrinol Metab. 2001 Nov;12(9):384-90. doi: 10.1016/s1043-2760(01)00441-6. Trends Endocrinol Metab. 2001. PMID: 11595539 Review.

8

The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer.

Mitsiades CS, Poulaki V, Mitsiades N. Mitsiades CS, et al. Among authors: mitsiades n. J Endocrinol. 2003 Aug;178(2):205-16. doi: 10.1677/joe.0.1780205. J Endocrinol. 2003. PMID: 12904168 Review.

9

Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes.

Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, Ju ST, Rook SL, Esser P, Mitsiades CS, Kirchhof B, Adamis AP, Aiello LP. Joussen AM, et al. Among authors: mitsiades n, mitsiades cs. FASEB J. 2003 Jan;17(1):76-8. doi: 10.1096/fj.02-0157fje. Epub 2002 Nov 15. FASEB J. 2003. PMID: 12475915

10

The role of Fas and FasL as mediators of anticancer chemotherapy.

Poulaki V, Mitsiades CS, Mitsiades N. Poulaki V, et al. Among authors: mitsiades n, mitsiades cs. Drug Resist Updat. 2001 Aug;4(4):233-42. doi: 10.1054/drup.2001.0210. Drug Resist Updat. 2001. PMID: 11991678 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters